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Abstract: The interleukin 28B (IL28B) rs12979860 polymorphism is associated with 
treatment outcome in hepatitis C virus (HCV) genotype 1 and 4 patients. Its association 
with the histological features of chronic hepatitis C and disease severity needs further 
clarifications. To assess the correlation between IL28B genotype, HCV genotype and liver 
biopsy findings in untreated patients. Materials and Methods: Pre-treatment liver biopsies 
from 335 HCV Caucasian patients (59% males, age 50 years) enrolled in the MIST study 
were staged for fibrosis and inflammation according to the METAVIR and the Ishak 
scoring systems; steatosis was dichotomized as <5% or ≥5%. IL28B was typed by Taqman 
Single Nucleotide Polymorphism (SNP) genotyping assay. HCV genotype was 1 in  
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151 (45%), 2 in 99 (30%), 3 in 50 (15%) and 4 in 35 (10%) patients. IL28B genotype was 
CC in 117 (34%), CT in 166 (49%) and TT in 52 (15%). At univariate analysis, the IL28B 
CC genotype was associated with severe portal inflammation in HCV-1 patients  
(CC vs. CT/TT: 86% vs. 63%, p = 0.005), severe lobular inflammation in HCV-2 patients 
(CC vs. CT/TT: 44% vs. 23%, p = 0.03), and less fatty infiltration in HCV-1 patients  
(CC vs. CT/TT: 72% vs. 51%, p = 0.02). Despite the lack of any association between 
IL28B and fibrosis stage, in HCV-3 patients IL28B CC correlated with METAVIR F3-F4  
(CC vs. CT/TT: 74% vs. 26%, p = 0.05). At multivariate analysis, the genotype CC 
remained associated with severe portal inflammation in HCV-1, only (Odds Ratio (OR): 
95% Confidence Interval (CI): 3.24 (1.23–8.51)). IL28B genotype is associated with the 
histological features of chronic hepatitis C in a HCV genotype dependent manner, with CC 
genotype being independently associated with severe portal inflammation. 
Keywords: interleukin 28B (IL28B) polymorphism; hepatitis C virus (HCV); histology; 
liver biopsy; fibrosis; necroinflammation; steatosis; natural history 
 
1. Introduction 
The rs12979860 interleukin 28B (IL28B) gene single-nucleotide polymorphisms (SNPs) is one of 
the few genetic predictors proven to be of clinical utility since it identifies patients with hepatitis C 
infection caused by genotype 1 or 4 who undergo spontaneous [1,2] or treatment-induced [3–5] viral 
clearance [6–9]. In chronically infected patients, however, there is enough data to support the interplay 
between host and environmental factors in the achievement of a permanent response to interferon (i.e., 
sustained virological response, SVR) including the stage of liver fibrosis, the degree of steatosis and of 
necroinflammation activity evaluated by liver biopsy. Interestingly, there is preliminary evidence for a 
heterogeneous distribution of histological markers of liver damage in patients with different IL28B 
genotypes suggesting an association between genetic control of interferon response and the natural 
course of chronic hepatitis C, thus extending our understanding of the IL28B functions beyond that of 
prediction of spontaneous resolution of acute hepatitis C virus HCV infection. 
Scrutinizing a large set of liver biopsies taken in patients with chronic hepatitis C of any genotype 
who subsequently entered a pragmatic trial of pegylated interferon (PegIFN) and ribavirin (RBV) 
therapy, we aimed to explore any potential association between IL28B rs12979860 genotypes and the 
histological features of the liver in our patient population. 
2. Results 
Among the 431 patients originally included in the MIST study, 89 (21%) did not have a pre-treatment 
biopsy specimen available for re-evaluation; 7 (2%) had an undetermined IL28B genotype; 335 (78%) 
patients were ultimately analyzed (Figure 1). There were 197 (59%) males, the median age was  
54 (21–73) years; liver disease was advanced (≥ F3) in 138 (41%). The HCV genotype distribution 
was 1 in 151 (45%), 2 in 99 (30%), 3 in 50 (15%) and 4 in 35 (10%). HCV-1 subtypes were not 
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equally represented, since HCV-1b was present in 132 (87%) patients; therefore data from HCV-1a 
and HCV-1b were cumulatively analyzed. IL28B genotype was CC in 117 (35%) and CT/TT in  
218 (65%) (Table 1). The median length of liver cores was 21 (12–54) mm; all LB were considered 
adequate for histological evaluation. 
Figure 1. Patient enrollment according to the original MIST study. 
 
*: Liver Biopsy 
Table 1. Epidemiological and clinical characteristics of the cohort according to IL28B genotype. 
Characteristics 
Overall  
(N = 335) 
IL28B CC  
(N = 117) 
IL28B CT/TT  
(N = 218) 
p-value 
Males ° 197 (59) 74 (63) 123 (56) 0.25 
Age, years * 54 (21–73) 55 (26–72) 24 (21–73) 0.42 
Body Mass Index * 25 (16–36) 25 (16–35) 25 (18–36) 0.91 
HCV genotype °     
1 151 (45) 43 (37) 108 (50) 
0.0008 
2 99 (30) 39 (33) 60 (27) 
3 50 (15) 28 (24) 22 (10) 
4 35 (10) 7 (6) 28 (13) 
HCV-RNA, IU/mL ** 774, 308 914, 086 743, 038 0.69 
ALT, U/L * 101 (9–691) 113 (22–691) 96 (9–486) 0.042 
γGT, U/L * 59 (11–633) 46 (12–633) 67 (11–502) < 0.0001 
Cholesterol, mg/dL * 172 (60–320) 174 (81–265) 170 (60–320) 0.08 
Tryglicerides, mg/dL * 92 (40–380) 86 (40–340) 95 (65–380) 0.13 
F3/F4 ° 138 (41) 48 (41) 90 (41) 1.0 
A2/A3 ° 167 (50) 59 (50) 108 (46) 0.9 
° N (%); * Median (range); ** Median. 
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2.1. Fibrosis 
According to METAVIR classification, fibrosis stage (F) was 0 in 10 (3%), 1 in 68 (20%), 2 in 119 
(36%), 3 in 80 (24%) and 4 in 58 (17%) patients. F3-F4 fibrosis was uniformly distributed among the 
cohort with respect to IL28B genotype (CC vs. CT/TT: 41% vs. 41%). Following stratification by 
HCV genotype, F3-F4 was more prevalent in HCV-3 patients carrying the IL28B CC genotype than in 
HCV-3 carriers of the IL28B T allele (CC vs. CT/TT: 50% vs. 23%, p = 0.045). Other than HCV-3 
genotype patients, no association between advanced liver disease (F3-F4) and IL28B genotype was 
found (CC vs. CT/TT: HCV-1 44% vs. 44%, p = 1.0; HCV-2 28% vs. 40%, p = 0.23; HCV-4 57% vs. 
50%, p = 0.74) (Figure 2). Among patients with advanced fibrosis (F3-F4), those infected with HCV-3 
had a higher prevalence of steatosis (74%) when compared to the remnants (HCV-1 43%,  
HCV-2 42%, HCV-4 49%; p < 0.0001). However, at univariate analysis steatosis did not emerge as 
predictor of advanced liver disease, since in HCV-3 patients AST and ALT values, IL28B CC 
genotype, fasting glucose levels and HOMA index were significantly associated with severe fibrosis. 
However, at multivariate analysis, AST values were independently associated with F3-F4 fibrosis,  
only (Table 2). 
Figure 2. Prevalence of advanced fibrosis (F3-F4) according to IL28B genotype (CC vs. CT/TT). 
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2.2. Inflammation 
In the overall cohort we found no association between METAVIR histological activity of hepatitis 
and IL28B genotype distribution, and the same was true when patients were analyzed as single  
HCV-genotype category (Table 3), with the exception of more severe portal infiltrates in HCV-1 
patients carrying the favorable IL28B CC genotype compared to other IL28B subgroups (CC vs. 
CT/TT: 86% vs. 63%, p = 0.005). In HCV-1 patients, univariate analysis identified older age and 
IL28B CC genotype as being associated to severe portal inflammation: both were confirmed by logistic 
regression analysis. Though HCV-2 patients with IL28B CC had more lobular inflammation (≥G3) than 
other IL28B subgroups (CC vs. CT/TT: 44% vs. 23%, p = 0.03), yet this association was not confirmed 
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at multivariate analysis (Table 3). Finally, IL28B polymorphisms were not associated with intensity of 
piecemeal necrosis or presence of confluent hepatitis. 
Table 2. Factors associated with the most relevant histological features according to viral 
genotypes at univariate and multivariate analysis. OR: Odds Ratio; CI: Confidence Interval. 
HCV genotype Histological features Univariate analysis Multivariate analysis OR (95% CI) 
HCV–1 
Portal inflammation 
Age  Age  1.04 (1.01–1.07) 
IL28B CC IL28B CC 3.24 (1.23–8.51) 
Steatosis 
Age γGT 1.02 (1.01–1.03) 
Body weight Body Mass Index 1.17 (1.03–1.33) 
Body Mass Index HOMA Index 2.10 (1.03–4.27) 
AST Tryglicerides 1.01 (1.00–1.02) 
γGT - - 
IL28B CT/TT - - 
Diabetes - - 
Glucose - - 
HOMA Index - - 
Tryglicerides - - 
HCV–2 Lobular inflammation 
AST AST 1.01 (1.00–1.01) 
ALT - - 
γGT - - 
IL28B CC - - 
HCV–3 Fibrosis 
AST AST 1.07 (1.02–1.11) 
ALT - - 
IL28B CC - - 
Glucose - - 
HOMA Index - - 
Table 3. Necroinflammation according to HCV genotype and IL28B (CC vs. CT/TT). 
Grading 
HCV-1 HCV-2 HCV-3 HCV-4 
CC  
(n = 43) 
CT/TT  
(n = 108) 
CC  
(n = 39) 
CT/TT  
(n = 60) 
CC  
(n = 28) 
CT/TT  
(n = 22) 
CC  
(n = 7) 
CT/TT  
(n = 28) 
METAVIR A ≥ 2 49% 50% 54% 48% 43% 45% 71% 54% 
Ishak         
Piecemeal ≥ 3 23% 13% 28% 18% 14% 10% 14% 18% 
Portal ≥ 3 86% 63% 69% 65% 50% 55% 71% 46% 
Lobular ≥ 3 19% 19% 44% 23% 21% 36% 71% 29% 
Confluent ≥ 3 23% 5% 18% 7% 14% 5% 0 14% 
p-values ns for all comparisons except for severe portal inflammation in HCV-1 (p = 0.005) and severe 
lobular inflammation in HCV-2 (p = 0.03). 
2.3. Steatosis 
Steatosis was identified in 161 (48%) patients: 65 (40%) HCV-1, 42 (26%) HCV-2, 37 (23%) 
HCV-3 and 17 (11%) HCV-4. Overall, patients with steatosis had lower levels of cholesterol (166 vs. 
175 mg/dL, p = 0.04) but higher levels of triglycerides (97 vs. 86 mg/dL; p = 0.004) than those without 
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steatosis. In HCV-1 patients, the IL28B CC genotype was associated with less steatosis than other 
IL28B genotypes (CC vs. CT/TT: 28% vs. 49%, p = 0.02), whilst no association was found in patients 
carrying other viral genotypes (Figure 3). Among the several factors that at univariate analysis were 
associated with the presence of histological steatosis, γGT, Body Mass Index (BMI), HOMA index and 
triglycerides emerged as independent variables at logistic regression, only (Table 2). According to the 
lipid profiles, the IL28B genotype did not impact on either cholesterol (p = 0.08) or triglycerides 
values (0.13) in all viral genotypes; however, among patients with histological steatosis, patients 
carrying the CC allele showed slight lower values of triglycerides (CC vs. non-CC: 85 vs. 104,  
p = 0.049) but not of cholesterol (CC vs. non-CC: 173 vs. 165; p = 0.72). 
Figure 3. Prevalence of steatosis (≥5%) according to IL28B genotype (CC vs. CT/TT). 
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CC, patients were more frequently males (p = 0.05) and had lower γGT levels (p = 0.001) 
3. Discussion 
The scrutiny of a large cohort of unselected patients infected with HCV genotype 1 to 4 who had a 
pretreatment liver biopsy available to assess necro-inflammation activity, fibrosis and steatosis in the 
liver, did not reveal any association between IL28B genotype and these histological features of chronic 
hepatitis C. This notwithstanding, in HCV-1 patients portal inflammation was to some extent 
associated to host genetic background, as the IL28B genotype CC emerged as an independent predictor 
of severe portal inflammation together with advanced patient age. 
This is an intriguing finding as HCV-1 patients are part of a cohort of early infected individuals in 
our community, represent the prevalent virus genotype population in Italy and are likely to better 
respond to IFN-based regimens that still represent the accessible form of anti-HCV therapy currently 
available in our country. 
We are confident that our findings are unlikely to be biased by criteria of patient selection as the 
study was conducted in a large cohort of patients with chronic hepatitis C who were consecutively 
recruited and found eligible to PegIFN and RBV therapy according to internationally agreed criteria. 
Only a minority of patients (21%) who underwent a liver biopsy in other Centers (but were enrolled in 
the MIST study once we could confirm their eligibility after reviewing their biopsy slides brought to 
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consultation) were excluded from this analysis. Importantly, the excluded population had a similar 
demography as the enrolled patients (data not shown). To further strengthen the robustness of our 
correlation study, we elected to assess necroinflammatory activity by both METAVIR and Ishak 
grading scores, with the hope that the latter would allow a more accurate definition of lobular 
topography of the necroinflammatory changes. Although we did not find any differences when 
stratifying the HAI scores obtained with the Ishak score by the IL28B genotype, the IL28B CC 
genotype was found to be associated to portal inflammation in HCV-1 as it was with lobular 
inflammation in HCV-2 patients. However, such an association was confirmed at multivariate analysis 
in HCV-1 patients only. Our findings, to some extent, corroborate a previous report of a correlation 
between histological features of liver inflammation and IL28B polymorphism in the overall HCV 
population [10]. In that study, in fact, though IL28BCC patients displayed higher total HAI scores  
(p = 0.007) as well as portal (p < 0.0001) and periportal (0.025) necroinflammation values than 
patients carrying the T allele, the lack of patient stratification by HCV genotype prevented 
demonstration of any virus specific correlation between histology and genes signaling interferon 
sensitivity. With all the caveats in the interpretation of portal infiltrate severity in our patients [11], 
portal inflammation could reflect the activation of the immune system against the infected hepatocytes 
which has been associated to the IFN sensitive IL28B genotype. IL28B CC patients, in fact, display a 
more pronounced activity of natural killer (NK) cells that are instrumental to viral clearance following 
treatments based on immunomodulatory drugs such as IFN and RBV [12,13]. Along this line are the 
findings of higher ALT values found in IL28BCC patients with intense histological necroinflammation 
due to HCV-1 [14], an observation built on the scrutiny of 1604 patients included in the IDEAL trial. 
Unfortunately, that study focusing on HCV-1 patients only missed any correlation analysis with the 
Ishak classification. 
The correlation between Il28B and liver inflammation was the focus of another study in a cohort of 
untreated patients with HCV-2 and HCV-3 patients which revealed a significant association between 
IL28B CC genotype and portal inflammation in HCV-3 patients but not in HCV-2 patients [15]. In 
other words, these authors could not find in HCV-2 infected patients the same association we found 
between lobular necrosis and IL28B CC genotype.  
We acknowledge, however, that the sample size of our HCV-3 group was small (15%), calling 
therefore for a cautious interpretation of our results, particularly considering that in the absence of any 
correlation between host genetic background and histological necroinflammation, the univariate 
analysis disclosed a statistically significant association between the IL28B CC genotype and liver 
fibrosis. Interestingly, these observations mimic the findings by Rembeck et al. of a trend for higher 
rates of liver fibrosis in IL28B CC patients with HCV-3 infection with respect to similar patients 
carrying the T allele [15]. In the thoroughly investigated Swiss cohort, Bochud and colleagues 
however failed to demonstrate any significant association between IL28B genotypes and fibrosis stage 
in patients HCV-3 using the rs860 SNP [16]. This could in part be explained by a direct cytoxic effect 
of HCV-3 strain on the liver as a consequence of its steatogenic and fibrosing activity: in HCV-3 
infected patients, both a hepatic derangement of lipid metabolism and a faster progression of liver 
fibrosis have been demonstrated in comparison to other HCV genotypes [17,18]. In our cohort of 
patients, we found a higher prevalence of advanced fibrosis (F3-F4) in HCV-3 patients when compared 
to other genotypes. Whilst among patients with advanced fibrosis, those infected with genotype 3 
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displayed the highest prevalence of hepatic steatosis, in this subgroup of patients no differences in 
histological steatosis were found when comparing F < 3 and F3-F4 patients (71% vs. 74%; p = 0.74). 
Given that chronic infection with HCV in IL28B CC patients has been consistently associated with 
higher serum HCV-RNA values, one could speculate that viral replication is increased as a 
consequence of a host genetic background that might result into accelerated fibrosis of the liver in 
HCV-3 IL28B CC patients. Still, we acknowledge that liver fibrosis is a dynamic parameter that can 
hardly be assessed with accuracy by any cross-sectional investigation like ours. 
More intriguing was the initial finding of a protective-like effect of IL28B CC genotype on the 
prevalence of histological steatosis in patients with chronic HCV-1 infection, which after adjustment 
for the other clinical features, was not confirmed by multivariate analysis. This is not a novel finding 
as steatosis was already found to prevail in carriers of the T allele in a cohort of 325 HCV-1 infected 
patients, an association that survived multivariate analysis [19]. In that study, IL28B CC patients had 
higher serum lipid levels that were thought to result from faster conversion of VLDL to LDL induced 
by the lipoprotein lipase activity. This enzyme in fact is suppressed by IFN-stimulating gene activity, 
which is down-regulated in patients carrying the CC genotype, causing low hepatic storage of lipids in 
the face of high serum levels of lipids [19]. As previously described, we also found higher levels of 
serum triglycerides in patients with steatosis, with patients carrying the T allele displaying the highest 
values. Although patients with steatosis showed slightly lower levels of total cholesterol, no 
differences were observed according to their IL28B genotype. 
We acknowledge that our study has several limitations, one above all that the cross-sectional design 
that prevents the dynamic assessment of the histological end points while restricting the analysis to the 
subpopulation of patients selected for IFN therapy might limit transferability of our findings to the 
whole HCV population. We acknowledge also the unavoidable bias of correlations being obtained 
following the scrutiny of liver biopsy cores which is still the gold standard for evaluating liver fibrosis 
and inflammation in HCV, but at the same time may be challenged by high rates of inter-observer 
variability and sampling errors [20]. We do hope however that these latter drawbacks were attenuated 
by the fact that histological readings were carried out on liver cores of appropriate length by two 
independent experts who were blind to the demographic data. 
In conclusion, this study provides the interesting finding that the segregation of IL28B genotypes is 
in accordance with different HCV related histological features in the liver. 
4. Materials and Methods 
4.1. Patient Population 
This study was a sub-analysis of the MIST study, which was originally designed to compare the 
safety and effectiveness of PegIFNα2a and Peg-IFNα2b therapy with RBV in untreated patients with 
chronic hepatitis C (CHC) [21]. Patients who were enrolled in the original study had a pre-treatment 
liver biopsy (LB) and retrospectively consented to IL28B genotype testing (rs12979860). Exclusion 
criteria were co-infection with hepatitis B virus and/or human immunodeficiency virus, drug 
dependence, elevated alcohol intake, autoimmune hepatitis and/or any other liver disease and 
decompensated liver disease. 
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The protocol was approved by the Institutional Review Board of our Department and conformed to 
the ethical guidelines of the 1975 Declaration of Helsinki. 
4.2. Laboratory Assessment 
Baseline anthropometric measurements, including the height and weight for calculating the body 
mass index, were recorded. An overnight (12 h) fasting blood sample was taken for routine analysis 
(e.g., alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), 
gamma-glutamyl transpeptidase (γGT), cholesterol, triglycerides, glucose and insulin. HOMA index 
was calculated according to the HOMA model formula, as previously described [22]. Serum HCV-RNA 
was quantified by Versant HCV-RNA 3.0 assay (bDNA 3.0; Bayer Corporation, Emeryville, CA, 
USA), with a sensitive limit of 615 IU/mL and a dynamic range from 615 to 7,700,000 IU/mL. 
4.3. IL28B Genotyping 
We analyzed the rs12979860 by real-time PCR on a LightCycler NANO instrument (Roche, 
Mannheim, Germany) using Taqman SNP genotyping assays according to manufacturers’ instructions 
(Applied Biosystems Inc., Foster City, CA, USA). 
4.4. Histological Assessment 
Liver biopsies (LBs) were performed with a 16-gauge Tru-cut needle (Uro-Cut 16G, TSK, Tokyo, 
Japan) and read by two independent pathologists (Roberta D’Ambrosio, Guido Ronchi) who were 
unaware of the patient’s IL28B genotype. Discrepancies were solved by consensus readings. LBs were 
considered adequate for histological analysis if they were longer than 10 mm and/or had at least  
12 portal tracts. Liver fibrosis stage was evaluated semi-quantitatively according to the METAVIR 
scoring system [23,24]. Similarly, the severity of hepatic inflammation was evaluated according to 
both the METAVIR [24] and the Ishak [25] grading systems. Liver steatosis was recorded and 
dichotomized as absent (<5%) or present (≥5%). 
4.5. Statistical Analysis 
Statistical analyses were conducted using the Mann-Whitney U test or the Student’s t-test for 
continuous variables and the χ2 or Fisher exact probability test for categorical data. A probability value 
of p < 0.05 was considered statistically significant. All variables with statistical significance at the 
univariate analysis were included in the final model and odds ratios (OR) and corresponding 95% 
confidence interval (95% CI) were computed. Calculations were done with Stata 10.0 statistical package. 
5. Conclusions 
IL28B genotype is associated with the histological features of chronic hepatitis C in a HCV 
genotype dependent manner, with CC genotype being independently associated with severe  
portal inflammation. 
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